These bio-techs can be tricky.
To mention just two: DNDN & HGSI.
Each FDA approval for what appeared to be significant therapies.
Yet, DNDN has collapsed. From the high 40's to current valuation.
As for HGSI, the buyout was far lower than one would have guessed.
But additional boosting by the analysts will be beneficial for VVUS.